Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy

Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy

Active immunotherapy may prevent the relapse of acute myeloid leukemia (AML) by inducing leukemia-specific T cells. Here, we investigated whether Wilms’ tumor 1 (WT1) and preferentially expressed antigen in melanoma (PRAME)-specific T cells could be induced upon the priming of healthy donor- and AML...

Full description

Bibliographic Details
Main Authors: van den Ancker, Willemijn, Ruben, Jurjen M., Westers, Theresia M., Wulandari, Dewi, Bontkes, Hetty J., Hooijberg, Erik, Stam, Anita G.M., Santegoets, Saskia J.A.M., Ossenkoppele, Gert J., de Gruijl, Tanja, van de Loosdrecht, Arjan
Format: Online
Language:English
Published: Landes Bioscience 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654602/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654602/

Similar Items